EMA Authorised: Bretaris Genuair (aclidinium bromide) — Covis Pharma Europe B.V.

View source ↗

Summary

The EMA authorised Bretaris Genuair (aclidinium bromide) for chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Bretaris Genuair (aclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Covis Pharma Europe B.V.. Decision date: 20/02/2025